Machine learning with magnetic resonance imaging for prediction of response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis

作者全名："Liang, Xueheng; Yu, Xingyan; Gao, Tianhu"

作者地址："[Liang, Xueheng; Gao, Tianhu] Peoples Hosp Chongqing Banan Dist, Dept Radiol, Chongqing, Peoples R China; [Yu, Xingyan] Chongqing Med Univ, Affiliated Hosp 1, Dept Nucl Med, Chongqing, Peoples R China"

通信作者："Gao, TH (通讯作者)，Peoples Hosp Chongqing Banan Dist, Dept Radiol, Chongqing, Peoples R China."

来源：EUROPEAN JOURNAL OF RADIOLOGY

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000820066100007

JCR分区：Q1

影响因子：3.3

年份：2022

卷号：150

期号：　

开始页：　

结束页：　

文献类型：Review

关键词：Breast neoplasms; Machine learning; Magnetic resonance imaging; Neoadjuvant therapy

摘要："Purpose: The aim of this meta-analysis was to determine the diagnostic accuracy of machine learning (ML) models with MRI in predicting pathological response to neoadjuvant chemotherapy in patients with breast cancer. Furthermore, we compared the pathologic complete response (pCR) prediction performance of ML + radiomics with that of a deep learning (DL) algorithm. Methods: A search for relevant studies published until December 20, 2021 was conducted in MEDLINE and EMBASE databases. The quality of the studies was assessed using the Quality Assessment of Diagnostic Accuracy Studies -2 criteria. The I-2 value assessed the heterogeneity of the included studies as well as the decision to adopt a random effects model. The area under the receiver operating characteristic curves (AUC) was pooled to quantify the predictive accuracy. Subgroup analysis, meta-regression analysis, and sensitivity analysis were performed to detect potential sources of study heterogeneity. A funnel plot was used to investigate publication bias. The PROSPERO ID of our study was CRD42022284071. Result: Seventeen eligible studies encompassing 3392 patients were evaluated in the analysis. ML + MRI showed high accuracy (AUC = 0.87, 95% CI = 0.84-0.91) in predicting response to neoadjuvant therapy. In subgroup analysis, the AUC of the DL subgroup (AUC = 0.92, 95% CI = 0.88-0.97) was higher than that of the ML + radiomics subgroup (AUC = 0.85, 95% CI = 0.82-0.90) (P = 0.030). In the ML + radiomics subgroup, the studies using MRI combined with other parameters (clinical or histopathologic information; AUC = 0.90, 95% CI = 0.85-0.96) reported better performance than studies using only MRI parameters (AUC = 0.82, 95% CI = 0.78-0.86) (P = 0.009). Conclusions: ML applied to MRI enabled moderate accuracy in predicting pathological response to neoadjuvant therapy in patients with breast cancer. Furthermore, the meta-analysis showed that DL had higher predictive accuracy than ML + radiomics."

基金机构：　

基金资助正文：